[go: up one dir, main page]

SI1844337T1 - Povezovalne spojine, imunogene spojine in peptidomimetiki - Google Patents

Povezovalne spojine, imunogene spojine in peptidomimetiki

Info

Publication number
SI1844337T1
SI1844337T1 SI200631654T SI200631654T SI1844337T1 SI 1844337 T1 SI1844337 T1 SI 1844337T1 SI 200631654 T SI200631654 T SI 200631654T SI 200631654 T SI200631654 T SI 200631654T SI 1844337 T1 SI1844337 T1 SI 1844337T1
Authority
SI
Slovenia
Prior art keywords
compounds
peptidomimetics
immunogenic
binding
binding compounds
Prior art date
Application number
SI200631654T
Other languages
English (en)
Inventor
Peter Timmerman
Wouter Cornelis Puijk
Jelle Wouter Slootstra
Dijk Evert Van
Robbert Hans Meloen
Original Assignee
Pepscan Systems B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pepscan Systems B.V. filed Critical Pepscan Systems B.V.
Publication of SI1844337T1 publication Critical patent/SI1844337T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5409IL-5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
SI200631654T 2005-01-24 2006-01-24 Povezovalne spojine, imunogene spojine in peptidomimetiki SI1844337T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05075174 2005-01-24
EP05077896 2005-12-16
EP06701606.3A EP1844337B1 (en) 2005-01-24 2006-01-24 Binding compounds, immunogenic compounds and peptidomimetics
PCT/NL2006/000036 WO2006078161A1 (en) 2005-01-24 2006-01-24 Binding compounds, immunogenic compounds and peptidomimetics

Publications (1)

Publication Number Publication Date
SI1844337T1 true SI1844337T1 (sl) 2013-11-29

Family

ID=36168379

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631654T SI1844337T1 (sl) 2005-01-24 2006-01-24 Povezovalne spojine, imunogene spojine in peptidomimetiki

Country Status (13)

Country Link
US (1) US7863239B2 (sl)
EP (1) EP1844337B1 (sl)
JP (1) JP5372380B2 (sl)
AU (1) AU2006206848B2 (sl)
CA (1) CA2595902C (sl)
CY (1) CY1114441T1 (sl)
DK (1) DK1844337T3 (sl)
ES (1) ES2428869T3 (sl)
NZ (1) NZ560504A (sl)
PL (1) PL1844337T3 (sl)
PT (1) PT1844337E (sl)
SI (1) SI1844337T1 (sl)
WO (1) WO2006078161A1 (sl)

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2555956T3 (es) * 2004-04-13 2016-01-11 St Vincent's Hospital Sydney Limited Método para modular el apetito
US7598356B2 (en) 2004-07-08 2009-10-06 Board of Regents of the University of Nebraska by and on behalf of the University of Nebraska Medical Center Method for purifying a protein of the cystine-knot superfamily
DE102005022047A1 (de) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung
AU2007277556B2 (en) * 2006-07-26 2012-11-29 Pepscan Systems B.V. Immunogenic compounds and protein mimics
BRPI0720306A2 (pt) 2006-12-14 2014-02-04 Aileron Therapeutics Inc Sistemas de macrociclização da bis-sufidrila
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CN104086641A (zh) 2007-02-23 2014-10-08 爱勒让治疗公司 三唑大环系统
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
US8680022B2 (en) * 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions
WO2009107771A1 (ja) * 2008-02-27 2009-09-03 国立大学法人大阪大学 金-酸化鉄複合ナノ粒子を用いたペプチドの合成方法
JP2012515172A (ja) 2009-01-14 2012-07-05 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) * 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
GB201012410D0 (en) 2010-07-23 2010-09-08 Medical Res Council Intracellular immunity
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
EP2726101B1 (en) 2011-06-30 2018-08-08 Genzyme Corporation Inhibitors of t-cell activation
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
PL2764140T3 (pl) 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
BR112014014917A2 (pt) * 2011-12-19 2018-05-15 Janssen R&D Ireland inibidores de fusão da membrana do hiv
GB201202268D0 (en) 2012-02-09 2012-03-28 Medical Res Council Intracellular immunity
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
EP2830646B1 (en) 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
ES2755104T3 (es) 2012-05-17 2020-04-21 Ra Pharmaceuticals Inc Inhibidores peptídicos y peptidomiméticos
US9556229B2 (en) 2012-05-18 2017-01-31 The Regents Of The University Of California Modification of peptides using a bis(thioether)arylbridge approach
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014116789A1 (en) * 2013-01-25 2014-07-31 Thymon, Llc Immunogenic and prophylactic compositions, methods of making same, and method for treating and preventing tnf-mediated disease and hiv-1 infection
KR101759687B1 (ko) 2013-01-25 2017-07-19 타이몬, 엘엘씨 순환하는 생물활성 가용성 tnf의 선택적 감소를 위한 조성물 및 tnf-매개 질환의 치료 방법
US9828415B2 (en) 2013-01-30 2017-11-28 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2767549A1 (en) 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26 antibodies and uses thereof
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
US9920096B2 (en) * 2013-06-25 2018-03-20 Sepia Pesquisa E Desenvolvimento Bradykinin receptor modulators and use thereof
SG11201602889TA (en) 2013-10-28 2016-05-30 Bicycle Therapeutics Ltd Novel polypeptides
US10822604B2 (en) * 2014-05-02 2020-11-03 Morphosys Ag Peptide libraries
KR101981532B1 (ko) 2014-06-12 2019-09-02 라 파마슈티컬스 인코포레이티드 보체 활성의 조절
JP6704358B2 (ja) 2014-07-30 2020-06-03 エヌジーエム バイオファーマシューティカルズ インコーポレイテッド 代謝障害を治療するための組成物および使用方法
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
MX389354B (es) 2014-09-24 2025-03-20 Aileron Therapeutics Inc Macrociclos peptidomimeticos y formulaciones de los mismos.
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
ES2799503T3 (es) 2014-10-31 2020-12-18 Ngm Biopharmaceuticals Inc Composiciones y procedimientos de uso para el tratamiento de trastornos metabólicos
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN109311956A (zh) 2015-08-25 2019-02-05 伊斯迪德股份公司 诱导组织形成的化合物及其应用
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
IL299622A (en) * 2015-09-17 2023-03-01 Histide Ag A pharmaceutical composition containing a growth receptor agonist and an adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and its uses
KR20180052726A (ko) * 2015-09-17 2018-05-18 히스티드 아게 신생물성 세포를 비-신생물성 세포로 전환시키기 위한 약제학적 회합물 및 이것의 용도
WO2017046229A1 (en) * 2015-09-17 2017-03-23 Histide Ag Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
RU2733720C2 (ru) 2015-12-16 2020-10-06 Ра Фармасьютикалз, Инк. Модуляторы активности комплемента
GB201600903D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Peptide derivaties
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
JP7021099B2 (ja) 2016-03-31 2022-02-18 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 結合タンパク質及びその使用方法
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Mt1-mmpに結合するためのペプチドリガンド
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
GB201808835D0 (en) 2018-05-30 2018-07-11 Bicyclerd Ltd Ligands and methods of selecting binding targets for such
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US11084857B2 (en) * 2018-12-05 2021-08-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Nsp-interleukin-10 proteins and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
BR112021011340A2 (pt) * 2018-12-13 2021-09-08 Bicycletx Limited Ligantes de peptídeo bicíclico específicos para mt1-mmp
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
GB201820320D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
CN113260420A (zh) 2018-12-21 2021-08-13 拜斯科阿迪有限公司 Pd-l1特异性的双环肽配体
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
WO2020178574A1 (en) 2019-03-04 2020-09-10 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
GB201914233D0 (en) 2019-10-02 2019-11-13 Bicyclerd Ltd Phage cyclisation assay
PL4464721T3 (pl) 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20230021419A1 (en) 2019-12-16 2023-01-26 Bicycletx Limited Bicyclic peptide ligands specific for il-17
GB201918559D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918558D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB201918557D0 (en) 2019-12-16 2020-01-29 Bicycle Tx Ltd Bicyclic peptide ligands specific for IL-17
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
CN115768456A (zh) * 2020-04-06 2023-03-07 拜斯科技术开发有限公司 Tslp特异性的双环肽配体
WO2021220011A1 (en) 2020-05-01 2021-11-04 Bicycletx Limited Anti-infective bicyclic peptide conjugates
JP2023526067A (ja) 2020-05-15 2023-06-20 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
GB202016331D0 (en) 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
KR20230122632A (ko) 2020-12-19 2023-08-22 올라플렉스, 인코포레이티드 헤어 스트레이트닝 및 셰이핑을 위한 조성물 및 사용방법
WO2022148968A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Anti-infective bicyclic peptide ligands
CN117120459A (zh) 2021-01-08 2023-11-24 拜斯科技术开发有限公司 抗感染双环肽配体
EP4274837A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
EP4274840A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
CN117043176A (zh) 2021-01-08 2023-11-10 拜斯科技术开发有限公司 抗感染双环肽配体
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CA3229976A1 (en) 2021-09-03 2023-03-09 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
GB202114282D0 (en) 2021-10-06 2021-11-17 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
GB202114279D0 (en) 2021-10-06 2021-11-17 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
GB202116266D0 (en) 2021-11-11 2021-12-29 Bicycletx Ltd Novel use
US20250101089A1 (en) 2022-01-24 2025-03-27 Cambridge Enterprise Limited Tau therapy
WO2024009108A1 (en) 2022-07-07 2024-01-11 Bicycletx Limited Anti-infective bicyclic peptide ligands
CN120835795A (zh) 2023-03-09 2025-10-24 拜斯科技术开发有限公司 双环毒素偶联物及其中间体的合成
GB202312685D0 (en) 2023-08-18 2023-10-04 Bicycletx Ltd Computer implemented method
WO2025046244A1 (en) 2023-09-01 2025-03-06 Bicycletx Limited Tlr3 binding bicyclic peptide ligands
GB202313403D0 (en) 2023-09-01 2023-10-18 Bicycletx Ltd Polypeptide screening
WO2025125652A1 (en) 2023-12-13 2025-06-19 Bicycletx Limited Combination therapy for use in treating cancer
WO2025191096A1 (en) 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US7994278B1 (en) * 1999-08-06 2011-08-09 Nobel Biosciences Llc Biologically active polypeptides derived from a novel early stage pregnancy factor designated maternin (MA)
FR2839452A1 (fr) * 2002-05-07 2003-11-14 Pf Medicament Utilisation de peptide derive de la sous-unite beta de l'hcg pour generer une reponse de type ctl antitumorale
GB0213878D0 (en) * 2002-06-17 2002-07-31 Protherics Plc Use
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound

Also Published As

Publication number Publication date
WO2006078161A1 (en) 2006-07-27
US7863239B2 (en) 2011-01-04
CY1114441T1 (el) 2016-08-31
EP1844337A1 (en) 2007-10-17
PT1844337E (pt) 2014-04-03
DK1844337T3 (da) 2013-09-30
CA2595902C (en) 2017-08-22
ES2428869T3 (es) 2013-11-12
CA2595902A1 (en) 2006-07-27
EP1844337B1 (en) 2013-07-03
JP2008529482A (ja) 2008-08-07
NZ560504A (en) 2009-07-31
JP5372380B2 (ja) 2013-12-18
US20080313749A1 (en) 2008-12-18
PL1844337T3 (pl) 2013-12-31
AU2006206848A1 (en) 2006-07-27
AU2006206848B2 (en) 2012-05-31

Similar Documents

Publication Publication Date Title
PL1844337T3 (pl) Związki wiążące, związki immunogenne i peptydomimetyki
GB0522658D0 (en) Composition
GB0519164D0 (en) Composition
GB0507167D0 (en) Composition
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) hair dye
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
GB0520523D0 (en) Object binding
GB0502341D0 (en) Composition
GB0506496D0 (en) Compound, composition and use
GB2427979B (en) Radiotelephones
GB2424448B (en) Keep
GB0513641D0 (en) Anti-egeing composition
GB2444005B (en) Compound, composition and use
GB0510286D0 (en) Composition
GB0519669D0 (en) Visors
GB2422575B (en) Files
GB0501646D0 (en) File
GB0520690D0 (en) Compound, composition and use
GB0515761D0 (en) Compound, composition and use
GB0506495D0 (en) Compound, composition and use
GB0520934D0 (en) Object binding
GB0525885D0 (en) Object binding
GB0504761D0 (en) Alfatie, Coliawel, Omaatie